Table 1.
Main characteristics of the patients recruited in the GHAS trial. Enrolled patients: patients with informed consent; age: years old ± standard deviation; ABI: ankle–brachial index; CRF: chronic renal failure; DM: diabetes mellitus; and rhGH: recombinant human growth hormone.
| Enrolled Patients | Sex | Age (Mean ± SD) | Comorbidity | Baseline ABI (Mean) | Rutherford class 5–6 |
|---|---|---|---|---|---|
| 36 | Male: 28 | 71 ± 12.7 | Heart disease:47% | 0.19 | 70.6% |
| Female:8 | DM:59% | ||||
| Neuropathy:57.6% | |||||
| CRF:26.5% | |||||
| Therapy | Dose | Duration of treatment | Follow-up | Follow-up Periods | |
| rhGH vs. Placebo | 0.4 mg/day | 8 weeks | 12 months | 0–2; 3–6; 7–12 months |